Cohort Studyhigh evidence
Proteomic resolution of the MASLD cardiometabolic spectrum identifies sex-driven endotypes and predicts systemic mortality.
Gut·July 29, 2026·PMID 42527119
Why it mattersMASLD risk stratification currently relies on liver-centric scores that may miss systemic cardiometabolic risk. This study identifies high-risk endotypes and a proteomic signature that captures mortality risk beyond liver fat, offering a biologically grounded tool for prognostication in patients with MASLD.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled